SB455 Relative to health plan coverage of GLP-1 medications.
Relative to health plan coverage of GLP-1 medications.
Impact Score — How Does This Bill Affect You?
Overall Impact Score
Mixed
Scale: 1 (harmful) to 10 (beneficial)
Your Wallet
Coverage mandates could save patients thousands per year on medications they need for chronic conditions.
Your Community
Better access to diabetes and obesity treatments improves public health outcomes and reduces long-term medical costs.
Your Freedom
Expands access to effective medications but adds to insurance mandates.
Status
Inexpedient to Legislate: Motion Adopted Voice Vote 05/14/2026 House Journal 13
Sponsor
Suzanne Prentiss (D)
The Short Version
Would address health insurance coverage for GLP-1 medications used to treat diabetes and obesity. These medications like Ozempic and Wegovy can be life-changing but cost over $1,000/month without insurance coverage.
Who's Behind This Bill?
Who Benefits
- ▲ People with diabetes needing GLP-1 medications
- ▲ Obese individuals who could benefit from these treatments
- ▲ Healthcare system through reduced diabetes complications
Who Pays the Price
- ▼ Health insurers facing new coverage requirements
- ▼ Employers and individuals who may see premium increases
Bill statuses as of May 2026. Check LegiScan or NH General Court for the latest.
This bill was auto-scored using AI analysis of the bill text and legislative data. Scores may be refined as we review more bills.